Redeye retains its positive view of CombinedX following the Q4 report.
Careium reported 1% y/y sales growth in Q4, leading to sales 1% above SEBe.
NoHo Partners reported Q4 EBIT of EUR 11.8m (-3.7% y/y), 4% above Vara Research consensus and 6% abo...
* Adj. EBITA -4% vs ABGSC and FactSet cons * Denmark remains challenging, will drive 1-2% est cuts *...
Taaleri’s Q4 2025 continuing earnings of EUR 12.2m increased by 17% y/y and came 18% above our estim...
Redeye updates on EG7 ahead of Q4-results (due 17 February) where we expect the results to remain la...
Nelly delivered a decent Q4 report in our view with c.
Redeye updates its estimates and valuation following MedCap’s Q4 2025 report.
Redeye updates its view following CTEK’s Q4 report.
* A solid report and new targets underpin long-term case * Adj.
Q4 showed a long-awaited return to organic growth driven by sales in Europe, while sales in the Amer...
* Cost actions showing up in margin improvements * Memory prices could support near-term growth reco...
Nettoomsättningen steg till 7 750 mkr med 4% organisk tillväxt och sex nya förvärv, inklusive intåg ...
Arctic Minerals har efter förvärvet av Rare Earth Energy Metals positionerat sig som ett nordiskt ko...
Redeye leaves a short comment following Cinclus’ announcement of having received positive CMC feedba...
Redeye comments on Faron’s announcement of a planned fully pre-emptive rights issue of approximately...
Aspo reports Q4 results on Feb 16. ESL should see more significant earnings gains from now on as out...
* Sales of SEK 432m, organic decline of 2% * Adj. EBITA of SEK 35m, and a margin of 8% * Continued d...
* Sales -5% vs ABG, adj. EBITA +23% on lower opex * West and Central continue to struggle, UK positi...
Redeye provides an initial take following the release of Optomed’s Q4 2025 report.
